Pharmacogenomics of drugs used to treat brain disorders

References

• Patel V, Chisholm D, Dua T, et al. Disease control priorities related to mental, neurological, and substance use disorders. 3rd ed. Vol. 4. Washington: World Bank Group; 2015.
   Google Scholar
• Murray CJ, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Geneva: Harvard University Press. 1996
   Google Scholar
• Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of mental and substance use disorders: findings from the global burden of disease study 2010. Lancet. 2013;382(9904):1575–1586. DOI:10.1016/S0140-6736(13)61611-6.
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1, 160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2163–2196. DOI:10.1016/S0140-6736(12)61729-2.
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for global burden of disease study 2013. Lancet. 2015;386(9995):743–800.
   PubMed Web of Science ®Google Scholar
• Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334–341.
   PubMed Web of Science ®Google Scholar
• Andlin-Sobocki P, Jönsson B, Wittchen HU, et al. Costs of disorders of the brain in Europe. Eur J Neurol. 2005;12(1):1–27. DOI:10.1111/j.1468-1331.2005.01202.x.
   PubMedGoogle Scholar
• Cacabelos R, editor. World Guide for Drug Use and Pharmacogenomics. ACorunna (Spain). EuroEspes Publishing; 2012.
   Google Scholar
• EuroPharmaGenics (EPG) [Internet]. Corunna: EuroEspes Publishing; 2012. [cited 2019 Dec]. Available from: http://europharmagenics.com/
   Google Scholar
• Cacabelos R, Tellado I, Cacabelos P. The epigenetic machinery in the life cycle and pharmacoepigenetics. In: Cacabelos R, editor. Pharmacoepigenetics. Oxford: Academic Press/Elsevier. 2019. p. 1–100.
   Google Scholar
• Cacabelos R, Carril JC, Sanmartín A, et al. Pharmacoepigenetic processors: epigenetic drugs, drug resistance, toxicoepigenetics, and nutriepigenetics. In: Cacabelos R, editor. Pharmacoepigenetics. Oxford: Academic Press/Elsevier; 2019. p. 191–424.
   Google Scholar
• Cacabelos R, Carril JC, Cacabelos P, et al. Pharmacogenomics of Alzheimer’s disease: genetic determinants of phenotypic variation and therapeutic outcome. J Genomic Med Pharmacogenomics. 2016;1(2):151–209.
   Google Scholar
• Cacabelos R. Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer’s disease and related risk factors. Future Neurol. 2018;13(2):71–86.
   Web of Science ®Google Scholar
• Cacabelos R. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics. Drug Dev Res. 2014;75(6):348–365.
   PubMed Web of Science ®Google Scholar
• Fujikura K, Ingelman-Sundberg M, Lauschke VM. Genetic variation in the human cytochrome P450 supergene family. Pharmacogenet Genomics. 2015;25(12):584–594. DOI:10.1097/FPC.0000000000000172.
   PubMed Web of Science ®Google Scholar
• Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006;11(2):126–135. DOI:10.1634/theoncologist.11-2-126.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019;12(5):407–442. DOI:10.1080/17512433.2019.1597706.
   PubMed Web of Science ®Google Scholar
• Laura A, Pratt LA, Brody DJ, et al. Antidepressant use in persons aged 12 and over: united States, 2005–2008. NCHS Data Brief. 2011;76:1–8.
   Google Scholar
• Lewer D, O’Reilly C, Mojtabai R, et al. Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors. Br J Psychiatry. 2015;207(3):221–226. DOI:10.1192/bjp.bp.114.156786.
   PubMed Web of Science ®Google Scholar
• Lynch TR, Whalley B, Hempel RJ, et al. Refractory depression: mechanisms and evaluation of radically open dialectical behaviour therapy (RO-DBT) [REFRAMED]: protocol for randomised trial. BMJ Open. 2015;5(7):e008857.
   PubMed Web of Science ®Google Scholar
• Hu TW. Perspectives: an international review of the national cost estimates of mental illness, 1990-2003. J Ment Health Policy Econ. 2006;9(1):3–13.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Heeringa S, Lakoma MD, et al. Individual and societal effects of mental disorders on earnings in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2008;165(6):703–711. DOI:10.1176/appi.ajp.2008.08010126.
   PubMed Web of Science ®Google Scholar
• Levinsohn PM, Klein DN, Seeley JR. Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course. J Am Acad Child Adolesc Psychiatry. 1995;34(4):454–463.
   PubMed Web of Science ®Google Scholar
• Coleman JRI, Gaspar HA, Bryois J, et al. The genetics of the mood disorder spectrum: genome-wide association analyses of more than 185, 000 cases and 439, 000 controls. Biol Psychiatry. 2019. S0006-3223(19)31813-X. DOI:10.1016/j.biopsych.2019.10.015.
   Google Scholar
• Perugi G, De Rossi P, Fagiolini A, et al. Personalized and precision medicine as informants for treatment management of bipolar disorder. Int Clin Psychopharmacol. 2019;34(4):189–205.
   PubMed Web of Science ®Google Scholar
• Calabrò M, Porcelli S, Crisafulli C, et al. Genetic variants associated with psychotic symptoms across psychiatric disorders. Neurosci Lett. 2020;720:134754.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Cacabelos P, Aliev G. Genomics and pharmacogenomics of antipsychotic drugs. Open J Psychiatry. 2013;3(1):46–139.
   Google Scholar
• Cacabelos R, Torrellas C. Pharmacogenomics of antidepressants. HSOA J Psychiatry Depression Anxiety. 2015;1:001.
   Google Scholar
• Cacabelos R. The path to personalized medicine in mental disorders. In: Ritsner MS, editor. The handbook of neuropsychiatric biomarkers, endophenotypes and genes. Vol. 4. Netherlands: Springer; 2011. p. 3–63.
   Google Scholar
• Gordovez FJA, McMahon FJ. The genetics of bipolar disorder. Mol Psychiatry. 2020;25(3):544–559. DOI:10.1038/s41380-019-0634-7.
   PubMed Web of Science ®Google Scholar
• Bixler EO, Kales A, Soldatos CR, et al. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry. 1979;136(10):1257–1262.
   PubMed Web of Science ®Google Scholar
• Ohayon MM. Epidemiological overview of sleep disorders in the general population. Sleep Med Res. 2011;2(1):1–9.
   Google Scholar
• Patterson SM, Hughes CM, Crealey G, et al. An evaluation of an adapted U.S. model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in Northern Ireland (Fleetwood Northern Ireland study). J Am Geriatr Soc. 2010;58(1):44–53. DOI:10.1111/j.1532-5415.2009.02617.x.
   PubMed Web of Science ®Google Scholar
• Barber ND, Alldred DP, Raynor DK, et al. Care homes’ use of medicines study: prevalence, causes and potential harm of medication errors in care homes for older people. Qual Saf Health Care. 2009;18(5):341–346. DOI:10.1136/qshc.2009.034231.
   PubMedGoogle Scholar
• Hughes CM, Lapane KL. Pharmacy interventions on prescribing in nursing homes: from evidence to practice. Ther Adv Drug Saf. 2011;2(3):103–112.
   PubMedGoogle Scholar
• Cacabelos R, Torrellas C, Tellado I, et al. Genomics, therapeutics and Pharmacogenomics of attention-deficit/hyperactivity disorder. In: López-Muñoz F, Álamo C, editors. Attention deficit hyperactivity disorder (ADHD). New York: Nova Science Publishers; 2015. p. 65–256.
   Google Scholar
• Cacabelos R, Torrellas C, Tellado I, et al. Genomics, pathogenesis, treatment and Pharmacogenomics of attention-deficit/hyperactivity disorder. Gen-T Int. 2016;4:8–134.
   Google Scholar
• Cacabelos R. Epigenetics and pharmacoepigenetics of neurodevelopmental and neuropsychiatric disorders. In: Cacabelos R, editor. Pharmacoepigenetics. Oxford: Academic Press/Elsevier; 2019. p. 609–709.
   Google Scholar
• Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014;383(9920):896–910.
   PubMed Web of Science ®Google Scholar
• Hu Z, Ying X, Huang L, et al. Association of human serotonin receptor 4 promoter methylation with autism spectrum disorder. Medicine (Baltimore). 2020;99(4):e18838.
   PubMed Web of Science ®Google Scholar
• Beck DB, Petracovici A, He C, et al. Delineation of a human mendelian disorder of the DNA demethylation machinery: TET3 deficiency. Am J Hum Genet. 2020;106(2):234–245. S0002-9297(19)30471-9. DOI:10.1016/j.ajhg.2019.12.007.
   PubMed Web of Science ®Google Scholar
• Vorstman JAS, Parr JR, Moreno-De-Luca D, et al. Autism genetics: opportunities and challenges for clinical translation. Nat Rev Genet. 2017;18(6):362–376. DOI:10.1038/nrg.2017.4.
   PubMed Web of Science ®Google Scholar
• Sokolova E, Oerlemans AM, Rommelse NN, et al. A causal and mediation analysis of the comorbidity between attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). J Autism Dev Disord. 2017;47(6):1595–1604.
   PubMed Web of Science ®Google Scholar
• Xu M, Xing Q, Li S, et al. Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):1026–1032.
   PubMed Web of Science ®Google Scholar
• Mas S, Gassó P, Lafuente A, et al. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. Pharmacogenomics J. 2016;16(5):439–445.
   PubMed Web of Science ®Google Scholar
• Zivković M, Mihaljević-Peles A, Bozina N, et al. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. J Clin Psychopharmacol. 2013;33(5):593–599.
   PubMed Web of Science ®Google Scholar
• Turčin A, Dolžan V, Porcelli S, et al. Adenosine hypothesis of antipsychotic drugs revisited: pharmacogenomics variation in nonacute schizophrenia. OMICS. 2016;20(5):283–289.
   PubMed Web of Science ®Google Scholar
• Gareeva AE, Zakirov DF, Valinurov RG, et al. Polymorphism of RGS2 gene: genetic markers of risk for schizophrenia and pharmacogenetic markers of typical neuroleptics efficiency. Mol Biol. 2013;47(6):934–941. DOI:10.1134/S0026893313060046.
   PubMed Web of Science ®Google Scholar
• Mas S, Gassó P, Ritter MA, et al. Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway. Eur Neuropsychopharmacol. 2015;25(1):51–59.
   PubMed Web of Science ®Google Scholar
• Lanning RK, Zai CC, Müller DJ. Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Pharmacogenomics. 2016;17(12):1339–1351.
   PubMed Web of Science ®Google Scholar
• Koola MM, Tsapakis EM, Wright P, et al. Association of tardive dyskinesia with variation in CYP2D6: is there a role for active metabolites? J Psychopharmacol. 2014;28(7):665–670.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kang SG. Genetics of tardive dyskinesia. Int Rev Neurobiol. 2011;98:231–264.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Syu A, Ishiguro H, et al. DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia. Pharmacogenomics J. 2013;13(1):27–34.
   PubMed Web of Science ®Google Scholar
• Greenbaum L, Alkelai A, Zozulinsky P, et al. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J. 2012;12(6):513–520.
   PubMed Web of Science ®Google Scholar
• Tiwari AK, Zai CC, Likhodi O, et al. Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. Pharmacogenomics J. 2012;12(3):260–266.
   PubMed Web of Science ®Google Scholar
• Zai CC, Tiwari AK, Mazzoco M, et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res. 2013;47(11):1760–1765.
   PubMed Web of Science ®Google Scholar
• Zai CC, Maes MS, Tiwari AK, et al. Genetics of tardive dyskinesia: promising leads and ways forward. J Neurol Sci. 2018a;389:28–34.
   PubMed Web of Science ®Google Scholar
• Zai CC, Tiwari AK, Zai GC, et al. New findings in pharmacogenetics of schizophrenia. Curr Opin Psychiatry. 2018;31(3):200–212.
   PubMed Web of Science ®Google Scholar
• Lu JY, Tiwari AK, Zai GC, et al. Association study of disrupted-in-schizophrenia-1 gene variants and tardive dyskinesia. Neurosci Lett. 2018;686:17–22.
   PubMed Web of Science ®Google Scholar
• Hongkaew Y, Medhasi S, Pasomsub E, et al. UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder. Pharmacogenomics J. 2018;18(6):740–748.
   PubMed Web of Science ®Google Scholar
• Nuntamool N, Ngamsamut N, Vanwong N, et al. Pharmacogenomics and efficacy of risperidone long-term treatment in Thai autistic children and adolescents. Basic Clin Pharmacol Toxicol. 2017;121(4):316–324.
   PubMed Web of Science ®Google Scholar
• Ngamsamut N, Hongkaew Y, Vanwong N, et al. 9-Hydroxyrisperidone-induced hyperprolactinaemia in Thai children and adolescents with autism spectrum disorder. Basic Clin Pharmacol Toxicol. 2016;119(3):267–272.
   PubMed Web of Science ®Google Scholar
• Sukasem C, Hongkaew Y, Ngamsamut N, et al. Impact of pharmacogenetic markers of CYP2D6 and DRD2 on prolactin response in risperidone-treated Thai children and adolescents with autism spectrum disorders. J Clin Psychopharmacol. 2016;36(2):141–146.
   PubMed Web of Science ®Google Scholar
• Puangpetch A, Srisawasdi P, Unaharassamee W, et al. Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia. Pharmgenomics Pers Med. 2019;12:155–166.
   PubMed Web of Science ®Google Scholar
• Sukasem C, Vanwong N, Srisawasdi P, et al. Pharmacogenetics of risperidone-induced insulin resistance in children and adolescents with autism spectrum disorder. Basic Clin Pharmacol Toxicol. 2018;123(1):42–50.
   PubMed Web of Science ®Google Scholar
• Puangpetch A, Unaharassamee W, Jiratjintana N, et al. Genetic polymorphisms of HTR2C, LEP and LEPR on metabolic syndromes in patients treated with atypical antipsychotic drugs. J Pharm Pharmacol. 2018;70(4):536–542.
   PubMed Web of Science ®Google Scholar
• Vanwong N, Srisawasdi P, Ngamsamut N, et al. Hyperuricemia in children and adolescents with autism spectrum disorder treated with risperidone: the risk factors for metabolic adverse effects. Front Pharmacol. 2017;7:527.
   PubMed Web of Science ®Google Scholar
• Manu P, Dima L, Shulman M, et al. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. 2015;132(2):97–108.
   PubMed Web of Science ®Google Scholar
• Chan LF, Zai C, Monda M, et al. Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics. 2013;14(11):1273–1281.
   PubMed Web of Science ®Google Scholar
• Xie C, Wang ZC, Liu XF, et al. Association between schizophrenia and single nucleotide polymorphisms in lipoprotein lipase gene in a Han Chinese population. Psychiatr Genet. 2011;21(6):307–314.
   PubMed Web of Science ®Google Scholar
• Kohlrausch FB, Severino-Gama C, Lobato MI, et al. The CYP1A2-163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients. Psychiatry Res. 2013;209(2):242–245.
   PubMed Web of Science ®Google Scholar
• Schuhmacher A, Becker T, Rujescu D, et al. Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics. J Psychiatr Res. 2012;46(8):1073–1080.
   PubMed Web of Science ®Google Scholar
• Landolt HP, Holst SC, Clinical VA. Experimental human sleep-wake pharmacogenetics. Handb Exp Pharmacol. 2019;253:207–241.
   PubMedGoogle Scholar
• Sani G, Perugi G, Tondo L. Treatment of bipolar disorder in a lifetime perspective: is lithium still the best choice? Clin Drug Investig. 2017;37(8):713–727.
   PubMed Web of Science ®Google Scholar
• Walss-Bass C, Fries GR. Are lithium effects dependent on genetic/epigenetic architecture? Neuropsychopharmacology. 2019;44(1):228.
   PubMed Web of Science ®Google Scholar
• Manchia M, Pisanu C, Squassina A. Lithium pharmacogenetics. Psychiatry Res. 2019;279:401.
   PubMed Web of Science ®Google Scholar
• Gomez-Sanchez CI, Carballo JJ, Riveiro-Alvarez R, et al. Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects. Sci Rep. 2017;7(1):10391.
   PubMedGoogle Scholar
• Cacabelos R, Torrellas C, Cacabelos P, et al. Pharmacogenetics of neurodegenerative disorders. In: Grech, Grossman, editors. Preventive and predictive genetics: towards Personalized Medicine. London: Springer; 2015. p. 173–240.
   Google Scholar
• Cacabelos R. Impact of genomic medicine on the future of neuropsychopharmacology. J Neuropsychopharmacol Mental Health. 2016;1:e101.
   Google Scholar
• Cacabelos R, Carril JC, Cacabelos P, et al. Pharmacogenetics of neurodegenerative disorders. Internal Med Rev. 2017;3(5):1–40. DOI:10.18103/imr.v3i6.472.
   Google Scholar
• Cacabelos R. Pharmacogenomics of Alzheimer’s and Parkinson’s diseases. Neurosci Lett. 2018; 133807. pii: S0304-3940(18)30624-4. DOI: 10.1016/j.neulet.2018.09.018.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Teijido O, Carril JC. Can cloud-based tools accelerate Alzheimer’s disease drug discovery? Expert Opin Drug Discov. 2016;11(3):215–223.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Have there been improvement in Alzheimer’s disease drug discovery over the past 5 years? Expert Opin Drug Discov. 2018;13(6):523–538.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Cacabelos P, Torrellas C, et al. Pharmacogenomics of Alzheimer’s disease: novel therapeutic strategies for drug development. Methods Mol Biol. 2014;1175:323–556.
   PubMedGoogle Scholar
• Cacabelos R, Goldgaber D, Vostrov A, et al. APOE-TOMM40 in the pharmacogenomics of dementia. J Pharmacogenomics Pharmacoproteomics. 2014;5:135.
   Google Scholar
• Cacabelos R, Torrellas C, Carrera I. Opportunities in pharmacogenomics for the treatment of Alzheimer’s disease. Future Neurol. 2015;10(3):229–252.
   Web of Science ®Google Scholar
• Cacabelos R, Torrellas C, Carrera I, et al. Novel therapeutic strategies for dementia. CNS Neurol Disord Drug Targets. 2016;15(2):141–241. DOI:10.2174/1871527315666160202121548.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Torrellas C, Tejido, et al. Pharmacogenetic considerations in the treatment of Alzheimer’s disease. Pharmacogenomics. 2016;17(9):1041–1074.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Population-level pharmacogenomics for precision drug development in dementia. Expert Rev Precis Med Drug Dev. 2018;3(3):163–188. DOI:10.1080/23808993.2018.1468218.
   Web of Science ®Google Scholar
• Cacabelos R, Cacabelos P, Carril JC. Epigenetics and pharmacoepigenetics of age-related neurodegenerative disorders. In: Cacabelos R, editor. Pharmacoepigenetics. Oxford (UK): Academic Press/Elsevier; 2019. p. 903–950.
   Google Scholar
• Cacabelos R. Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics. Neuropsychiat Dis Treat. 2007;3(3):303–333.
   PubMedGoogle Scholar
• Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2013;52(4):225–241. DOI:10.1007/s40262-013-0038-9.
   PubMed Web of Science ®Google Scholar
• Pilotto A, Franceschi M, D’Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology. 2009;73(10):761–767. DOI:10.1212/WNL.0b013e3181b6bbe3.
   PubMed Web of Science ®Google Scholar
• Xiao T, Jiao B, Zhang W, et al. Effect of the CYP2D6 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease: a systematic review and meta-analysis. CNS Drugs. 2016;30(10):899–907.
   PubMed Web of Science ®Google Scholar
• Albani D, Martinelli BF, Biella G, et al. Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer’s disease patients. J Alzheimers Dis. 2012;30(4):745–749. DOI:10.3233/JAD-2012-112123.
   PubMed Web of Science ®Google Scholar
• Seripa D, Bizzarro A, Pilotto A, et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer’s disease. Pharmacogenet Genomics. 2011;21(4):225–230. DOI:10.1097/FPC.0b013e32833f984c.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Zheng X, Miao Y, et al. Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease. Am J Med Sci. 2013;345(3):222–226. DOI:10.1097/MAJ.0b013e318255a8f9.
   PubMed Web of Science ®Google Scholar
• Yaowaluk T, Senanarong V, Limwongse C, et al. Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer’s disease and vascular dementia. Pharmacogenomics Pers Med. 2019;12:209–224.
   PubMed Web of Science ®Google Scholar
• Magliulo L, Dahl ML, Lombardi G, et al. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Eur J Clin Pharmacol. 2011;67(1):47–54. DOI:10.1007/s00228-010-0883-5.
   PubMed Web of Science ®Google Scholar
• De Beaumont L, Pelleieux S, Lamarre-Théroux L, et al. Alzheimer’s disease cooperative study. Butyrylcholinesterase K and apolipoprotein E-ɛ4 reduce the age of onset of Alzheimer’s disease, accelerate cognitive decline, and modulate donepezil response in mild cognitively impaired subjects. J Alzheimers Dis. 2016;54(3):913–922. DOI:10.3233/JAD-160373.
   PubMed Web of Science ®Google Scholar
• Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41(10):719–739.
   PubMed Web of Science ®Google Scholar
• Lilienfeld S. Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2006;8(2):159–176.
   Google Scholar
• Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383–1392.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Brett M, Van Osselaer N, et al. Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. J Clin Pharmacol. 2002;42(9):1002–1010. DOI:10.1177/0091270002042009007.
   PubMed Web of Science ®Google Scholar
• Mannens GS, Snel CA, Hendrickx J, et al. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos. 2002;30(5):553–563. DOI:10.1124/dmd.30.5.553.
   PubMed Web of Science ®Google Scholar
• Noetzli M, Guidi M, Ebbing K, et al. Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations. Ther Drug Monit. 2013;35(2):270–275. DOI:10.1097/FTD.0b013e318282ff02.
   PubMed Web of Science ®Google Scholar
• Clarke JA, Cutler M, Gong I, et al. Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study. Am J Geriatr Pharmacother. 2011;9(4):224–233. DOI:10.1016/j.amjopharm.2011.07.003.
   PubMedGoogle Scholar
• Bentué-Ferrer D, Tribut O, Polard E, et al. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs. 2003;17(13):947–963. DOI:10.2165/00023210-200317130-00002.
   PubMed Web of Science ®Google Scholar
• Huang F, Fu Y. A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, in healthy subjects and patients. Curr Clin Pharmacol. 2010;5(2):115–124.
   PubMedGoogle Scholar
• Zhai XJ, Lu YN. Food-drug interactions: effect of capsaicin on the pharmacokinetics of galantamine in rats. Xenobiotica. 2012;42(11):1151–1155.
   PubMed Web of Science ®Google Scholar
• Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther. 1998;20(4):634–647.
   PubMed Web of Science ®Google Scholar
• Sonali N, Tripathi M, Sagar R, et al. Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer’s patients. CNS Neurosci Ther. 2013;19(2):91–97. DOI:10.1111/cns.2013.19.issue-2.
   PubMed Web of Science ®Google Scholar
• Yoon H, Myung W, Lim SW, et al. Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer’s disease. Pharmacopsychiatry. 2015;48(3):111–117.
   PubMed Web of Science ®Google Scholar
• Clarelli F, Mascia E, Santangelo R, et al. CHRNA7 Gene and response to cholinesterase Inhibitors in an Italian cohort of Alzheimer’s disease patients. J Alzheimers Dis. 2016;52(4):1203–1208.
   PubMed Web of Science ®Google Scholar
• Martinelli-Boneschi F, Giacalone G, Magnani G, et al. Pharmacogenomics in Alzheimer’s disease: a genome-wide association study of response to cholinesterase inhibitors. Neurobiol Aging. 2013;34(6):1711.e7-13.
   PubMed Web of Science ®Google Scholar
• Qiu WQ, Mwamburi M, Besser LM, et al. Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer’s disease in the absence of apolipoprotein E4 allele. J Alzheimers Dis. 2013;37(2):421–428.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhou X, Zhang Q. Effectiveness and safety of memantine treatment for Alzheimer’s disease. J Alzheimers Dis. 2013;36(3):445–458.
   PubMed Web of Science ®Google Scholar
• Micuda S, Mundlova L, Anzenbacherova E, et al. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Eur J Clin Pharmacol. 2004;60(8):583–589. DOI:10.1007/s00228-004-0825-1.
   PubMed Web of Science ®Google Scholar
• Noetzli M, Guidi M, Ebbing K, et al. Population pharmacokinetic study of memantine: effects of clinical and genetic factors. Clin Pharmacokinet. 2013;52(3):211–223. DOI:10.1007/s40262-013-0032-2.
   PubMed Web of Science ®Google Scholar
• von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol. 2005;15(4):473–490. DOI:10.1016/j.euroneuro.2005.04.007.
   PubMed Web of Science ®Google Scholar
• Zou YM, Liu J, Tian ZY, et al. Systematic review of the prevalence and incidence of Parkinson’s disease in the People’s Republic of China. Neuropsychiatr Dis Treat. 2015;15:1467–1472.
   Google Scholar
• Hirsch L, Jette N, Frolkis A, et al. The incidence of Parkinson’s Disease: a systematic review and meta-analysis. Neuroepidemiology. 2016;46(4):292–300.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–1590.
   PubMed Web of Science ®Google Scholar
• Riedel O, Bitters D, Amann U, et al. Estimating the prevalence of Parkinson’s disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data. Int J Geriatr Psychiatry. 2016;31(8):938–943. DOI:10.1002/gps.4414.
   PubMed Web of Science ®Google Scholar
• Agúndez JA, García-Martín E, Alonso-Navarro H, et al. Anti-Parkinson’s disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol. 2013;9(7):859–874.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Parkinson’s disease: from pathogenesis to pharmacogenomics. Int J Mol Sci. 2017;18(3):551.
   PubMed Web of Science ®Google Scholar
• Titova N, Chaudhuri KR. Personalized medicine and nonmotor symptoms in Parkinson’s disease. Int Rev Neurobiol. 2017;134:1257–1281.
   PubMed Web of Science ®Google Scholar
• Dos Santos EUD, Sampaio TF. Tenório Dos Santos AD, et al. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson’s disease. J Pharm Pharmacol. 2019;71(2):206–212.
   PubMed Web of Science ®Google Scholar
• Moreau C, Meguig S, Corvol JC, et al. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease. Brain. 2015;138(5):1271–1283.
   PubMedGoogle Scholar
• Rieck M, Schumacher-Schuh AF, Altmann V, et al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients. Pharmacogenomics. 2012;13(15):1701–1710.
   PubMed Web of Science ®Google Scholar
• Rieck M, Schumacher-Schuh AF, Callegari-Jacques SM, et al. Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson’s disease patients? Pharmacogenomics. 2015;16(6):573–582.
   PubMed Web of Science ®Google Scholar
• Schumacher-Schuh AF, Altmann V, Rieck M, et al. Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson’s disease patients. Pharmacogenomics J. 2014;14(3):289–294.
   PubMed Web of Science ®Google Scholar
• Rieck M, Schumacher-Schuh AF, Altmann V, et al. Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson’s disease. Pharmacogenomics J. 2018;18(1):196–200.
   PubMed Web of Science ®Google Scholar
• Masellis M, Collinson S, Freeman N, et al. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain. 2016;139(7):2050–2062.
   PubMedGoogle Scholar
• Corvol JC, Bonnet C, Charbonnier-Beaupel F, et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson’s disease: a randomized crossover clinical trial. Ann Neurol. 2011;69(1):111–118.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Fernández-Novoa L, Alejo R, et al. E-PodoFavalin-15999 (Atremorine®)-induced dopamine response in Parkinson’s disease: pharmacogenetics-related effects. J Genomic Med Pharmacogenomics. 2016;1:1–26.
   Google Scholar
• Cacabelos R, Carrera I, Alejo R, et al. Pharmacogenetics of Atremorine-induced neuroprotection and dopamine response in Parkinson’s disease. Planta Med. 2019. DOI:10-1055/a-1013-7686.
   PubMed Web of Science ®Google Scholar
• Lill CM, Luessi F, Alcina A, et al. Genome-wide significant association with seven novel multiple sclerosis risk loci. J Med Genet. 2015;52(12):848–855.
   PubMed Web of Science ®Google Scholar
• Sokolova EA, Malkova NA, Korobko DS, et al. Association of SNPs of CD40 gene with multiple sclerosis in Russians. PLoS One. 2013;8(4):e61032.
   PubMed Web of Science ®Google Scholar
• Grossman I, Knappertz V, Laifenfeld D, et al. Pharmacogenomics strategies to optimize treatments for multiple sclerosis: insights from clinical research. Prog Neurobiol. 2017;152:114–130.
   PubMed Web of Science ®Google Scholar
• Jafarzadeh A, Jamali M, Mahdavi R, et al. Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program. J mol neurosc. 2015;55(4):891–897. DOI:10.1007/s12031-014-0443-z.
   PubMed Web of Science ®Google Scholar
• Mahdavi R, Jamali M, Rostami M, et al. FOXP3 polymorphism rs2232365 and its association with multiple sclerosis susceptibility. Tehran Univ Med J. 2016;74(6):425–432.
   Google Scholar
• Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, Rituximab, and injectable therapies. JAMA Neurol. 2019. DOI:10.1001/jamaneurol.2019.3365.
   PubMed Web of Science ®Google Scholar
• Mahurkar S, Moldovan M, Suppiah V, et al. Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Pharmacogenomics J. 2017;17(4):312–318.
   PubMed Web of Science ®Google Scholar
• Clarelli F, Liberatore G, Sorosina M, et al. Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis. Pharmacogenomics J. 2017;17(1):84–91.
   PubMed Web of Science ®Google Scholar
• Malhotra S, Río J, Urcelay E, et al. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis. Brain. 2015;138(3):644–652.
   PubMedGoogle Scholar
• Kulakova OG, Tsareva EY, Lvovs D, et al. Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate. Pharmacogenomics. 2014;15(5):679–685.
   PubMed Web of Science ®Google Scholar
• Kulakova OG, Tsareva EY, Boyko AN, et al. Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients. Pharmacogenomics. 2012;13(15):1689–1700.
   PubMed Web of Science ®Google Scholar
• Weber F, Cepok S, Wolf C, et al. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients. Pharmacogenomics J. 2012;12(3):238–245.
   PubMed Web of Science ®Google Scholar
• Núñez C, Cénit MC, Alvarez-Lafuente R, et al. HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis. J Med Genet. 2014;51(6):395–400.
   PubMed Web of Science ®Google Scholar
• Bedri SK, Fink K, Manouchehrinia A, et al. Multiple sclerosis treatment effects on plasma cytokine receptor levels. Clin Immunol. 2018;187:15–25.
   PubMed Web of Science ®Google Scholar
• De Andres C, García MI, Goicoechea H1, et al. Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers. Pharmacogenomics J. 2018;18(1):98–105.
   PubMed Web of Science ®Google Scholar
• Ross CJ, Towfic F, Shankar J, et al. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. Genome Med. 2017;9(1):50.
   PubMedGoogle Scholar
• Nicolas A, Kenna KP, Renton AE, et al. Genome-wide analyses identify KIF5A as a novel ALS Gene. Neuron. 2018;97(6):1268–1283.
   PubMed Web of Science ®Google Scholar
• Dardiotis E, Aloizou AM, Siokas V, et al. The role of microRNAs in patients with amyotrophic lateral sclerosis. J Mol Neurosci. 2018;66(4):617–628.
   PubMed Web of Science ®Google Scholar
• Mehanna R, Hunter C, Davidson A, et al. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28(2):210–215.
   PubMed Web of Science ®Google Scholar
• Truelsen T, Piechowski-Józwiak B, Bonita R, et al. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol. 2006;13(6):581–598.
   PubMed Web of Science ®Google Scholar
• Zhang FL, Guo ZN, Wu YH, et al. Prevalence of stroke and associated risk factors: a population based cross sectional study from northeast China. BMJ Open. 2017;7(9):e015758.
   PubMed Web of Science ®Google Scholar
• Teh WL, Abdin E, Vaingankar JA, et al. Prevalence of stroke, risk factors, disability and care needs in older adults in Singapore: results from the WiSE study. BMJ Open. 2018;8(3):e020285.
   PubMed Web of Science ®Google Scholar
• Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520, 000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet. 2018;50(4):524–537.
   PubMed Web of Science ®Google Scholar
• Xu K, Liu X, Ott J, et al. The combined effects of cardiovascular disease related SNPs on ischemic stroke. J Neurol Sci. 2018;388:141–145.
   PubMed Web of Science ®Google Scholar
• Marini S, Crawford K, Morotti A, et al. Association of apolipoprotein E with intracerebral hemorrhage risk by race/ethnicity: a meta-analysis. JAMA Neurol. 2019;76(4):480–491. DOI:10.1001/jamaneurol.2018.4519.
   PubMed Web of Science ®Google Scholar
• Woo D, Deka R, Falcone GJ, et al. Apolipoprotein E, statins, and risk of intracerebral hemorrhage. Stroke. 2013;44(11):3013–3017.
   PubMed Web of Science ®Google Scholar
• Woo D, Falcone GJ, Devan WJ, et al. Meta-analysis of genome-wide association studies identifies 1q22 as a susceptibility locus for intracerebral hemorrhage. Am J Hum Genet. 2014;94(4):511–521.
   PubMed Web of Science ®Google Scholar
• Anderson CD, Falcone GJ, Phuah CL, et al. Genetic variants in CETP increase risk of intracerebral hemorrhage. Ann Neurol. 2016;80(5):730–740.
   PubMed Web of Science ®Google Scholar
• Tsai CT, Chang SN, Chang SH, et al. Renin-angiotensin system gene polymorphisms predict the risk of stroke in patients with atrial fibrillation: a 10-year prospective follow-up study. Heart Rhythm. 2014;11(8):1384–1390.
   PubMed Web of Science ®Google Scholar
• Marini S, Devan WJ, Radmanesh F, et al. 17p12 Influences hematoma volume and outcome in spontaneous intracerebral hemorrhage. Stroke. 2018;49(7):1618–1625.
   PubMed Web of Science ®Google Scholar
• Traylor M, Malik R, Nalls MA, et al. Genetic variation at 16q24.2 is associated with small vessel stroke. Ann Neurol. 2017;81(3):383–394.
   PubMed Web of Science ®Google Scholar
• Rannikmäe K, Sivakumaran V, Millar H, et al. COL4A2 is associated with lacunar ischemic stroke and deep ICH: meta-analyses among 21, 500 cases and 40, 600 controls. Neurology. 2017;89(17):1829–1839.
   PubMed Web of Science ®Google Scholar
• Muiño E, Gallego-Fabrega C, Cullell N, et al. Systematic review of cysteine-sparing NOTCH3 missense mutations in patients with clinical suspicion of CADASIL. Int J Mol Sci. 2017;18(9):E1964.
   PubMed Web of Science ®Google Scholar
• Muiño E, Krupinski J, Carrera C, et al. An inflammatory polymorphisms risk scoring system for the differentiation of ischemic stroke subtypes. Mediators Inflamm. 2015;2015:569714.
   PubMed Web of Science ®Google Scholar
• Debette S, Kamatani Y, Metso TM, et al. Common variation in PHACTR1 is associated with susceptibility to cervical artery dissection. Nat Genet. 2015;47(1):78–83.
   PubMed Web of Science ®Google Scholar
• Esih K, Goričar K, Dolžan V, et al. The association between antioxidant enzyme polymorphisms and cerebral palsy after perinatal hypoxic-ischaemic encephalopathy. Eur J Paediatr Neurol. 2016;20(5):704–708.
   PubMed Web of Science ®Google Scholar
• Danese E, Raimondi S, Montagnana M, et al. Effect of CYP4F2, VKORC1, and CYP2C9 in influencing coumarin dose: a single-patient data meta-analysis in more than 15, 000 Individuals. Clin Pharmacol Ther. 2019;105(6):1477–1491.
   PubMed Web of Science ®Google Scholar
• Yi X, Cheng W, Lin J, et al. Interaction between COX-1 and COX-2 variants associated with aspirin resistance in Chinese stroke patients. J Stroke Cerebrovasc Dis. 2016;25(9):2136–2144.
   PubMed Web of Science ®Google Scholar
• Gallego-Fabrega C, Carrera C, Reny JL, et al. PPM1A methylation is associated with vascular recurrence in aspirin-treated patients. Stroke. 2016;47(7):1926–1929.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhou Y, Pan Y, et al. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics J. 2018;18(6):713–720.
   PubMed Web of Science ®Google Scholar
• McDonough CW, McClure LA, Mitchell BD, et al. CYP2C19 metabolizer status and clopidogrel efficacy in the secondary prevention of small subcortical strokes (SPS3) study. J Am Heart Assoc. 2015;4(6):e001652.
   PubMed Web of Science ®Google Scholar
• Duconge J, Hernandez-Suarez DF. Potential usefulness of clopidogrel pharmacogenetics in cerebral endovascular procedures and carotid artery stenting. Curr Clin Pharmacol. 2017;12(1):11–17.
   PubMed Web of Science ®Google Scholar
• Kapedanovska-Nestorovska A, Dimovski AJ, Sterjev Z, et al. The AKR1D1*36 (rs1872930) allelic variant is independently associated with clopidogrel treatment outcome. Pharmgenomics Pers Med. 2019;12:287–295.
   PubMed Web of Science ®Google Scholar
• Sychev DA, Baturina OA, Mirzaev KB, et al. CYP2C19*17 may increase the risk of death among patients with an acute coronaty syndrome and non-valvular atrial fibrillation who receive clopidogrel and rivaroxaban. Pharmacogenomics Pers Med. 2020;13:29–37.
   PubMed Web of Science ®Google Scholar
• Gallego-Fabrega C, Carrera C, Reny JL, et al. TRAF3 epigenetic regulation is associated with vascular recurrence in patients with ischemic stroke. Stroke. 2016;47(5):1180–1186.
   PubMed Web of Science ®Google Scholar
• Mega JL, Walker JR, Ruff CT, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2280–2287.
   PubMed Web of Science ®Google Scholar
• Seeger J, Wöhrle J. Apixaban: an update of the evidence for its place in the prevention of stroke in patients with atrial fibrillation. Care evidence. 2020;15:1–6. DOI:10.2147/CE.S172935.
   PubMed Web of Science ®Google Scholar
• Chen W, Wu L, Liu X, et al. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement. Int J Clin Pharmacol Ther. 2017;55(2):126–132.
   PubMed Web of Science ®Google Scholar
• Kamali X, Wulasihan M1, Yang YC, et al. Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang. Lipids Health Dis. 2013;12(1):149.
   PubMedGoogle Scholar
• Magvanjav O, McDonough CW, Gong Y, et al. Pharmacogenetic associations of β1-adrenergic receptor polymorphisms with cardiovascular outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). Stroke. 2017;48(5):1337–1343.
   PubMed Web of Science ®Google Scholar
• Yi X, Zhou Q, Wang C, et al. Platelet receptor Gene (P2Y12, P2Y1) and platelet glycoprotein Gene (GPIIIa) polymorphisms are associated with antiplatelet drug responsiveness and clinical outcomes after acute minor ischemic stroke. Eur J Clin Pharmacol. 2017;73(4):437–443.
   PubMed Web of Science ®Google Scholar
• Sørensen IF, Vazquez AI, Irvin MR, et al. Pharmacogenetic effects of ‘candidate gene complexes’ on stroke in the GenHAT study. Pharmacogenet Genomics. 2014;24(11):556–563.
   PubMedGoogle Scholar
• Kampouraki E, Kamali F. Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation. Expert Opin Drug Metab Toxicol. 2019;15(6):449–458. DOI:10.1080/17425255.2019.1623878.
   PubMed Web of Science ®Google Scholar
• Saliba W, Rennert HS, Barnett-Griness O, et al. Association of statin use with spontaneous intracerebral hemorrhage: a cohort study. Neurology. 2018;91(5):400–409.
   Web of Science ®Google Scholar
• Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012;92(1):112–117.
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63(1):157–181.
   PubMed Web of Science ®Google Scholar
• Arrigoni E, Del Re M, Fidilio L, et al. Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins. Int J Mol Sci. 2017;18(1):E104.
   PubMed Web of Science ®Google Scholar
• Ward NC, Watts GF, Eckel RH, et al. Statin toxicity: Mechanistic insights and clinical implications. Circ Res. 2019;124:328–350.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Chen SQ, Ma LY, et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J. 2018;18(6):721–729. DOI:10.1038/s41397-018-0054-0.
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Johnson SG, Caudle KE1, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96(4):423–428.
   PubMed Web of Science ®Google Scholar
• Isackson PJ, Wang J, Zia M, et al. RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms. Pharmacogenomics. 2018;19(16):1235–1249.
   PubMed Web of Science ®Google Scholar
• Floyd JS, Bloch KM, Brody JA, et al. Pharmacogenomics of statin-related myopathy: meta-analysis of rare variants from whole-exome sequencing. PLoS One. 2019;14(6):e0218115.
   PubMed Web of Science ®Google Scholar
• Sai K, Kajinami K, Akao H, et al. A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients. Drug Metab Pharmacokinet. 2016;31(6):467–470.
   PubMed Web of Science ®Google Scholar
• Pomes LM, Guglielmetti M, Bertamino E, et al. Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain. 2019;20(1):56.
   PubMedGoogle Scholar
• Anttila V, Wessman M, Kallela M, et al. Genetics of migraine. Handb Clin Neurol. 2018;148:493–503.
   PubMedGoogle Scholar
• Capi M, Gentile G, Lionetto L, et al. Pharmacogenetic considerations for migraine therapies. Expert Opin Drug Metab Toxicol. 2018;14(11):1161–1167.
   PubMed Web of Science ®Google Scholar
• Katsarou MS, Papasavva M, Latsi R, et al. Population-based analysis of cluster headache-associated genetic polymorphisms. J Mol Neurosci. 2018;65(3):367–376.
   PubMed Web of Science ®Google Scholar
• Schürks M, Frahnow A, Diener HC, et al. Bi-allelic and tri-allelic 5-HTTLPR polymorphisms and triptan non-response in cluster headache. J Headache Pain. 2014;15(1):46.
   PubMedGoogle Scholar
• Gan J, Cai Q, Galer P, et al. Mapping the knowledge structure and trends of epilepsy genetics over the past decade: a co-word analysis based on medical subject headings terms. Medicine (Baltimore). 2019;98(32):e16782.
   PubMed Web of Science ®Google Scholar
• Al-Eitan LN, Al-Dalalah IM, Mustafa MM, et al. Effects of MTHFR and ABCC2 gene polymorphisms on antiepileptic drug responsiveness in Jordanian epileptic patients. Pharmgenomics Pers Med. 2019;12:87–95.
   PubMed Web of Science ®Google Scholar
• Thijs RD, Surges R, O’Brien TJ, et al. Epilepsy in adults. Lancet. 2019;393(10172):689–701.
   PubMed Web of Science ®Google Scholar
• He ZW, Qu J, Zhang Y, et al. PRRT2 mutations are related to febrile seizures in epileptic patients. Int J Mol Sci. 2014;15(12):23408–23417.
   PubMed Web of Science ®Google Scholar
• Haerian BS, Baum L, Kwan P, et al. Contribution of GABRG2 polymorphisms to risk of epilepsy and febrile seizure: a multicenter cohort study and meta-analysis. Mol Neurobiol. 2016;53(8):5457–5467.
   PubMed Web of Science ®Google Scholar
• Zhu -M-M, Li H-L, Shi L-H, et al. The pharmacogenomics of valproic acid. J Hum Genet. 2017;62(12):1009–1014.
   PubMed Web of Science ®Google Scholar
• Zhu X, Yun W, Sun X, et al. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics. 2014;15(15):1867–1879.
   PubMed Web of Science ®Google Scholar
• Wang P, Lin XQ, Cai WK, et al. Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis. Eur J Clin Pharmacol. 2018;74(4):433–442.
   PubMed Web of Science ®Google Scholar
• Hung CC, Ho JL, Chang WL, et al. Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics. 2011;12(8):1107–1117.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang J, Wu X, et al. Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese. Pharmacogenomics. 2016;17(18):2007–2014. DOI:10.2217/pgs-2016-0093.
   PubMed Web of Science ®Google Scholar
• Noai M, Soraoka H, Kajiwara A, et al. Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. Acta Neurol Scand. 2016;133(3):216–223.
   PubMed Web of Science ®Google Scholar
• Li H, Wang X, Zhou Y, et al. Association of LEPR and ANKK1 gene polymorphisms with weight gain in epilepsy patients receiving valproic acid. Int J Neuropsychopharmacol. 2015;18(7):pyv021.
   PubMed Web of Science ®Google Scholar
• Xu S, Chen Y, Zhao M, et al. Population pharmacokinetics of valproic acid in epileptic children: effects of clinical and genetic factors. Eur J Pharm Sci. 2018;122:170–178.
   PubMed Web of Science ®Google Scholar
• Wen ZP, Fan SS, Du C, et al. Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients. Pharmacogenomics. 2016;17(11):1219–1225. DOI:10.2217/pgs-2016-0030.
   PubMed Web of Science ®Google Scholar
• Li Q, Li QQ, Jia JN, et al. Sodium valproate ameliorates neuronal apoptosis in a kainic acid model of epilepsy via enhancing PKC-dependent GABAAR γ2 serine 327 phosphorylation. Neurochem Res. 2018;43(12):2343–2352.
   PubMed Web of Science ®Google Scholar
• Ogusu N, Saruwatari J, Nakashima H, et al. Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. PLoS One. 2014;9(11):e111066.
   PubMed Web of Science ®Google Scholar
• Koomdee N, Pratoomwun J, Jantararoungtong T, et al. Association of HLA-A and HLA-B alleles with lamotrigine-induced cutaneous adverse drug reactions in the Thai population. Front Pharmacol. 2017;8:879.
   PubMed Web of Science ®Google Scholar
• Shirzadi M, Reimers A, Helde G, et al. No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants *2(P24T) or *3(L48V) in Norwegian patients. Seizure. 2017;45:169–171.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu S, Wang Z, et al. A population pharmacokinetic-pharmacogenetic model of lamotrigine in Chinese children with wpilepsy. Ther Drug Monit. 2018;40(6):730–737.
   PubMed Web of Science ®Google Scholar
• Shen CH, Zhang YX, Lu RY, et al. Specific OCT1 and ABCG2 polymorphisms are associated with lamotrigine concentrations in Chinese patients with epilepsy. Epilepsy Res. 2016;127:186–190.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang X, Li H, et al. Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with lamotrigine trough concentrations in epilepsy patients. Drug Metab Pharmacokinet. 2015;30(4):282–287.
   PubMed Web of Science ®Google Scholar
• Phillips EJ, Sukasem C, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharmacol Ther. 2018;103(4):574–581. DOI:10.1002/cpt.1004.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yu Y, Nie X, et al. Association between HLA-B*15:02 and oxcarbazepine-induced cutaneous adverse reaction: a meta-analysis. Pharmacogenomics. 2018;19(6):547–552.
   PubMed Web of Science ®Google Scholar
• Chen CB, Hsiao YH, Wu T, et al. Taiwan severe cutaneous adverse reaction consortium. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology. 2017;88(1):78–86.
   PubMed Web of Science ®Google Scholar
• Cheung YK, Cheng SH, Chan EJ, et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013;54(7):1307–1314.
   PubMed Web of Science ®Google Scholar
• Aoki M, Hosono N, Takata S, et al. New pharmacogenetic test for detecting an HLA-A*31: 01 allele using the InvaderPlus assay. Pharmacogenet Genomics. 2012;22(6):441–446.
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M, Wang CW, Hung SI, et al. HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. Allergy. 2019;74(11):2227–2230.
   PubMed Web of Science ®Google Scholar
• Sukasem C, Chaichan C, Nakkrut T, et al. Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients. J Immunol Res. 2018;2018:2780272.
   PubMed Web of Science ®Google Scholar
• Kulkantrakorn K, Tassaneeyakul W, Tiamkao S, et al. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract. 2012r;12(3):202–208.
   PubMed Web of Science ®Google Scholar
• Zhou BT, Zhou QH, Yin JY, et al. Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS Neurosci Ther. 2012;18(7):566–572.
   PubMed Web of Science ®Google Scholar
• Shen C, Zhang B, Liu Z, et al. Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy. Seizure. 2017;51:102–106.
   PubMed Web of Science ®Google Scholar
• Djordjevic N, Jankovic SM, Milovanovic JR. Pharmacokinetics and pharmacogenetics of carbamazepine in children. Eur J Drug Metab Pharmacokinet. 2017;42(5):729–744.
   PubMed Web of Science ®Google Scholar
• Wang P, Yin T, Ma HY, et al. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy Res. 2015;117:52–57.
   PubMed Web of Science ®Google Scholar
• Ma CL, Jiao Z, Wu XY, et al. Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy. Pharmacogenomics. 2015a;16(13):1499–1512.
   PubMed Web of Science ®Google Scholar
• Ma CL, Wu XY, Jiao Z, et al. SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy. Pharmacogenomics. 2015b;16(4):347–360.
   PubMed Web of Science ®Google Scholar
• Hung CC, Chang WL, Ho JL, et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics. 2012a;13(2):159–169.
   PubMed Web of Science ®Google Scholar
• Hung CC, Huang HC, Gao YH, et al. Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients. Pharmacogenomics. 2012b;13(12):1339–1349.
   PubMed Web of Science ®Google Scholar
• Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014;312(5):525–534.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Prabmeechai N, Sukasem C, et al. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics. 2016;26(5):225–234.
   PubMed Web of Science ®Google Scholar
• Su SC, Chen CB, Chang WC, et al. HLA Alleles and CYP2C9*3 as predictors of phenytoin hypersensitivity in East Asians. Clin Pharmacol Ther. 2019;105(2):476–485.
   PubMed Web of Science ®Google Scholar
• McCormack M, Gui H, Ingason A, et al. Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology. 2018;90(4):e332–e341.
   PubMed Web of Science ®Google Scholar
• Glauser TA, Holland K, O’Brien VP, et al. Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy. Ann Neurol. 2017;81(3):444–453.
   PubMed Web of Science ®Google Scholar
• Rogawski MA. The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs. Epilepsia. 2013;54(2):33–40.
   PubMedGoogle Scholar
• Haerian BS, Roslan H, Raymond AA, et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. Seizure. 2010;19(6):339–346.
   PubMed Web of Science ®Google Scholar
• Ajmi M, Boujaafar S, Zouari N, et al. Association between ABCB1 polymorphisms and response to first-generation antiepileptic drugs in a Tunisian epileptic population. Int J Neurosci. 2018;128(8):705–714.
   PubMed Web of Science ®Google Scholar
• Qu J, Zhou BT, Yin JY, et al. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. CNS Neurosci Ther. 2012;18(8):647–651.
   PubMed Web of Science ®Google Scholar
• Lv N, Qu J, Long H, et al. Association study between polymorphisms in the CACNA1A, CACNA1C, and CACNA1H genes and drug-resistant epilepsy in the Chinese Han population. Seizure. 2015;30:64–69.
   PubMed Web of Science ®Google Scholar
• Daci A, Bozalija A, Jashari F, et al. Individualizing treatment approaches for epileptic patients with glucose transporter type1 (GLUT-1) deficiency. Int J Mol Sci. 2018;19(1):s.
   Web of Science ®Google Scholar
• Ma CL, Wu XY, Zheng J, et al. Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics. 2014;15(10):1323–1336.
   PubMed Web of Science ®Google Scholar
• Sha’ari HM, Haerian BS, Baum L, et al. ABCC2 rs2273697 and rs3740066 polymorphisms and resistance to antiepileptic drugs in Asia Pacific epilepsy cohorts. Pharmacogenomics. 2014;15(4):459–466.
   PubMed Web of Science ®Google Scholar
• Lotte J, Bast T, Borusiak P, et al. Effectiveness of antiepileptic therapy in patients with PCDH19 mutations. Seizure. 2016;35:106–110.
   PubMed Web of Science ®Google Scholar
• Kouga T, Shimbo H, Iai M, et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome. Brain Dev. 2015;37(2):243–249.
   PubMed Web of Science ®Google Scholar
• Hung CC, Chen PL, Huang WM, et al. Gene-wide tagging study of the effects of common genetic polymorphisms in the α subunits of the GABA(A) receptor on epilepsy treatment response. Pharmacogenomics. 2013;14(15):1849–1856. DOI:10.2217/pgs.13.158.
   PubMed Web of Science ®Google Scholar
• Beckett RD, Kisor DF, Smith T, et al. Systematic evaluation of clinical practice guidelines for pharmacogenomics. Pharmacogenomics. 2018;19(8):693–700. DOI:10.2217/pgs-2018-0024.
   PubMed Web of Science ®Google Scholar
• Cecchin E, Roncato R, Guchelaar HJ, et al. Ubiquitous pharmacogenomics (U-PGx): the time for implementation is now. An horizon2020 program to drive pharmacogenomics into clinical practice. Curr Pharm Biotechnol. 2017;18(3):204–209.
   PubMed Web of Science ®Google Scholar
• Qin W, Du Z, Xiao J, et al. Evaluation of clinical impact of pharmacogenomics knowledge involved in CPIC guidelines on Chinese pediatric patients. Pharmacogenomics. 2020;21(3):209–219.
   PubMed Web of Science ®Google Scholar
• Fabbri C, Serretti A. Genetics of treatment outcomes in major depressive disorder: present and future. Clin Psychopharmacol Neurosci. 2020;18(1):1–9.
   PubMed Web of Science ®Google Scholar
• Popejoy AB. Diversity in precision medicine and pharmacogenetics: methodlogical and conceptual considerations for broadening participation. Pharmac Pers Med. 2019;12:257–271.
   Web of Science ®Google Scholar
• Cacabelos R, Torrellas C. Epigenetics of aging and Alzheimer’s disease: implications for pharmacogenomics and drug response. Int J Mol Sci. 2015;16(12):30483–30543.
   PubMed Web of Science ®Google Scholar
• Torrellas C, Carril JC, Cacabelos R. Optimization of antidepressant use with pharmacogenetic strategies. Cur Genomics. 2017;18:442–449.
   PubMed Web of Science ®Google Scholar
• Cheung SR, Summerour RB, Cui X, et al. Testing for CYP polymorphisms is associated with a reduction in the frequency of changes in psychotropic prescriptions made by community psychiatrists. J Genomic Med Pharmacogenomics. 2016;1:76–80.
   Google Scholar
• Haga SB. Pharmacogenomic testing in pediatrics: navigating the ethical, social, and legal challenges. Pharmacs Pers Med. 2019;12:273–285.
   Web of Science ®Google Scholar
• Heath L, Gray SL, Boudreau DM, et al. Cumulative antidepressant use and risk of dementia in a prospective cohort study. J Am Geriatr Soc. 2018;66(10):1948–1955.
   PubMed Web of Science ®Google Scholar
• Kirgaval RS, Revanakar S, Srirangapattna C. Prevalence of extrapyramidal side effects in patients on antipsychotics drugs at a tertiary care center. J Psychiatry. 2017;20:419.
   Google Scholar
• Cacabelos R. Pathoepigenetics: the role of epigenetic biomarkers in disease pathogenesis. In: Cacabelos R, editor. Pharmacoepigenetics. Oxford: Academic Press/Elsevier; 2019. p. 139–189.
   Google Scholar
• Roses AD, Saunders AM, Lutz MW, et al. New applications of disease genetics and pharmacogenetics to drug development. Curr Opin Pharmacol. 2014;14:81–89.
   PubMed Web of Science ®Google Scholar
• Otsubo Y. Use of pharmacogenomics and biomarkers in the development of new drugs for Alzheimer disease in Japan. Clin Ther. 2015;37(8):1627–1631.
   PubMed Web of Science ®Google Scholar
• Ferroni L, Della Puppa A, D’Avella D, et al. Tissue engineering strategies as tools for personalized meningioma treatment. Artif Organs. 2015;39(7):E114–26.
   PubMed Web of Science ®Google Scholar
• Carlson RJ, Doucette JR, Nazarali AJ. Current developments in pharmacogenomics of multiple sclerosis. Cell Mol Neurobiol. 2014;34(8):1081–1085.
   PubMed Web of Science ®Google Scholar
• Dendrou CA, Bell JI, Fugger L. A clinical conundrum: the detrimental effect of TNF antagonists in multiple sclerosis. Pharmacogenomics. 2013;14(12):1397–1404.
   PubMed Web of Science ®Google Scholar
• Benjamin ER, Della Valle MC, Wu X, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19(4):430–438.
   PubMed Web of Science ®Google Scholar
• Bennett LL, Turcotte K. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease. Drug Des Devel Ther. 2015;9:4639–4647.
   PubMed Web of Science ®Google Scholar
• Dervan AP, Deverka PA, Trosman JR, et al. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Genet Med. 2017;19(5):559–567.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Carril JC, Cacabelos N, et al. Sirtuins in Alzheimer’s disease: SIRT2-related genophenotypes and implications for pharmacoepigenetics. Int J Mol Sci. 2019;20(5):E1249.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Torrellas C. Epigenetic drug discovery for Alzheimer’s disease. Expert Opin Drug Discov. 2014;9(9):1059–1086.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. How plausible is an Alzheimer’s disease vaccine? Expert Opin Drug Discov. 2019;1–6. DOI:10.1080/17460441.2019.1667329
   PubMed Web of Science ®Google Scholar
• Song M, Yang X, Ren X, et al. Mapping cis-regulatory chromatin contacts in neural cells links neuropsychiatric disorder risk variants to target genes. Nat Genet. 2019;51(8):1252–1262.
   PubMed Web of Science ®Google Scholar
• Rexach J, Lee H, Martinez-Agosto JA, et al. Clinical application of next-generation sequencing to the practice of neurology. Lancet Neurol. 2019;18(5):492–503.
   PubMed Web of Science ®Google Scholar
• Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia. 2018;59(12):2179–2193.
   PubMed Web of Science ®Google Scholar
• Kong ST, Ho CS, Ho PC, et al. Prevalence of drug resistant epilepsy in adults with epilepsy attending a neurology clinic of a tertiary referral hospital in Singapore. Epilepsy Res. 2014;108(7):1253–1262.
   PubMed Web of Science ®Google Scholar
• Kalozoumi G, Kel-Margoulis O, Vafiadaki E, et al. Glial responses during epileptogenesis in Mus musculus point to potential therapeutic targets. PLoS One. 2018;13(8):e0201742.
   PubMed Web of Science ®Google Scholar
• Orlandi A, Paolino MC, Striano P, et al. Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy. Expert Opin Drug Metab Toxicol. 2018;14(5):505–512.
   PubMed Web of Science ®Google Scholar
• Mitchell D, Guertin JR, Dubois A, et al. A discrete event simulation model to assess the economic value of a hypothetical pharmacogenomics test for statin-induced myopathy in patients initiating a statin in secondary cardiovascular prevention. Mol Diagn Ther. 2018;22(2):241–254.
   PubMed Web of Science ®Google Scholar
• Chen Z, Liew D, Kwan P. Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment. Neurology. 2016;86(12):1086–1094.
   PubMed Web of Science ®Google Scholar
• Mitropoulou C, Fragoulakis V, Bozina N, et al. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Pharmacogenomics. 2015;16(2):137–148.
   PubMed Web of Science ®Google Scholar
• You JH. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis. Pharmacogenet Genomics. 2014;24(1):6–14.
   PubMed Web of Science ®Google Scholar
• Pink J, Pirmohamed M, Lane S, et al. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther. 2014;95(2):199–207.
   PubMed Web of Science ®Google Scholar
• Dionne F, Mitton C, Rassekh R, et al. Economic impact of a genetic test for cisplatin-induced ototoxicity. Pharmacogenomics J. 2012;12(3):205–213.
   PubMed Web of Science ®Google Scholar
• Lala A, Berger JS, Sharma G, et al. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. J Thromb Haemost. 2013;11(1):81–91.
   PubMed Web of Science ®Google Scholar
• Powell G, Holmes EA, Plumpton CO, et al. Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients’ and physicians’ preferences for testing and service delivery. Br J Clin Pharmacol. 2015;80(5):1149–1159.
   PubMed Web of Science ®Google Scholar
• Ostergren JE, Gornick MC, Carere DA, et al. How well do customers of direct-to-consumer personal genomic testing services comprehend genetic test results? Findings from the Impact of personal genomics study. Public Health Genomics. 2015;18(4):216–224.
   PubMed Web of Science ®Google Scholar
• Mao XY, Dai JX, Zhou HH, et al. Brain tumor modeling using the CRISPR/Cas9 system: state of the art and view to the future. Oncotarget. 2016;7(22):33461–33471.
   PubMedGoogle Scholar
• Danielyan L, Beer-Hammer S, Stolzing A, et al. Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer’s and Parkinson’s disease. Cell Transplant. 2014;23(1):123–139.
   Google Scholar